SynthesisJournal of the American Heart Association2025
Major Adverse Cardiovascular Events in Angiogenesis Inhibitor-Based Cancer Therapy: A Systematic Review and Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis inhibitors (AIs) are effective in cancer therapy due to their ability to suppress tumor vasculature. However, these agents are associated with significant cardiovascular toxicities, including hypertension, thrombosis, and heart failure, which may increase when combined with other cancer treatments, such as chemotherapy or immunotherapy. This meta-analysis aims to evaluate the cardiovascular adverse events linked to AIs, focusing on their types, incidence, and severity of these adverse events to provide a clearer understanding of the cardiovascular risks associated with AIs.
methodsA systematic review was conducted for randomized controlled trials that assessed AI therapies. The data from 64 studies involving 27 639 patients were analyzed using a random-effects model. Major adverse cardiovascular events such as hypertension, thrombosis, arrhythmias, myocardial ischemia, and left ventricular dysfunction were the primary outcomes.
resultsThe analysis revealed that AI treatment significantly increased the incidence of hypertension (relative risk [RR], 3.28 [95% CI, 2.82-4.30]), myocardial ischemia or infarction events (RR, 2.09 [95% CI, 1.05-4.17]), arrhythmia events (RR, 1.25 [95% CI, 0.90-1.74]), thrombotic events (RR, 1.46 [95% CI, 1.11-1.92]), and left ventricular dysfunction (RR, 2.00 [95% CI, 1.18-3.41]). Subgroup analyses indicated that the combination of AIs with chemotherapy or other targeted therapies heightened these risks.
conclusionsAIs significantly increase the risk of cardiovascular events in patients with cancer, particularly when combined with other treatments. Clinicians should balance the benefits and cardiovascular risks of AIs and consider strategies to reduce these adverse effects. Further research is needed to refine these insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.